The deal will help Pfizer beef up and diversify its obesity drug pipeline following its $10 billion acquisition of obesity ...

After beefing up the target of its global cost-savings drive once again, Pfizer is continuing to see its plan through with ...

Pfizer’s recent bidding war for an obesity biotech clearly hasn’t satiated the pharma’s appetite for new GLP-1 therapies—at least going by ...

Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, ...

This comes just under a month after Pfizer finalised a deal to acquire Metsera following a bidding war with Novo Nordisk.

Pfizer's latest narrative update leaves its fair value estimate steady at about $29.08 per share, even as analysts fine tune assumptions around the company’s long term trajectory. Slightly softer ...

Pfizer's coronavirus vaccine could face some headwinds in the near future. The company will enter a period of patent cliffs ...

Pfizer is in the midst of an aggressive, multi-year cost-cutting effort, which so far has left nearly 2,000 people jobless.

A potentially $2 billion deal with a subsidiary of Shanghai-based Fosun Pharma gives Pfizer a new chance at an oral weight ...

Pfizer offers value with a strong dividend, Metsera obesity expansion, PADCEV/Keytruda approval, and an oncology pipeline.

The anti-obesity drug market has the potential to be massive, with multiple analysts projecting it may reach at least $100 billion by 2030. As a result, many top healthcare companies are vying for a ...

Amy Schulman is the second veteran of the pharmaceutical industry that Elevance has added to its board this year.